Cel Sci (CVM) Profit After Tax (2010 - 2026)
Cel Sci (CVM) posted Profit After Tax of -$5.5 million for Q1 2026, little changed sequentially from -$5.5 million in Q4 2025, and up 16.84% YoY from -$4.7 million in Q1 2025.
Cel Sci (CVM) Profit After Tax (2010 - 2026) Analysis & Trends
Cel Sci has reported Profit After Tax for 17 years, with the latest figure at -$5.5 million in Q1 2026.
- Quarterly Profit After Tax rose 16.84% year-over-year to -$5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$22.7 million (up 16.76% YoY) and the FY2025 annual result came in at -$25.4 million, up 7.86% from the prior year.
- Profit After Tax steadied at -$5.5 million in Q1 2026 per CVM's latest filing, from -$5.5 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$5.5 million in Q1 2026 and troughed at -$9.9 million in Q2 2022.
- A 5-year average of -$7.3 million and a median of -$7.1 million in 2024 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax declined 5.42% in 2024, then rose 22.67% in 2025.
- Over 5 years, Profit After Tax stood at -$7.9 million in 2022, then increased by 14.57% to -$6.7 million in 2023, then declined by 5.42% to -$7.1 million in 2024, then increased by 22.67% to -$5.5 million in 2025, then climbed by 0.07% to -$5.5 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$5.5 million, -$5.5 million, and -$6.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | -5.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.47 Mn |
| Dec 31, 2025 | -5.47 Mn |
| Sep 30, 2025 | -6.10 Mn |
| Jun 30, 2025 | -5.66 Mn |
| Mar 31, 2025 | -6.57 Mn |
| Dec 31, 2024 | -7.07 Mn |
| Sep 30, 2024 | -6.77 Mn |
| Jun 30, 2024 | -6.86 Mn |
| Mar 31, 2024 | -7.24 Mn |
| Dec 31, 2023 | -6.71 Mn |
| Sep 30, 2023 | -7.63 Mn |
| Jun 30, 2023 | -8.37 Mn |
| Mar 31, 2023 | -8.34 Mn |
| Dec 31, 2022 | -7.85 Mn |
| Sep 30, 2022 | -8.46 Mn |
| Jun 30, 2022 | -9.93 Mn |
| Mar 31, 2022 | -9.82 Mn |
| Dec 31, 2021 | -8.78 Mn |
| Sep 30, 2021 | -8.20 Mn |
| Jun 30, 2021 | -10.44 Mn |